FDAsafety guidance83% confidence
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to ACADIA Pharmaceuticals Inc..
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neurology · Alzheimer's Disease
- Sub-indication
- General
Related signal: ACADIA Pharmaceuticals initiates ACP-204 trials for Alzheimer's Disease Psychosis